Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.64 |
| ▸ | THRB | P10828 | 8/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413248 | 0.97 | TGFBR1 (0.61) | TGFBR1THRBMAPK14 | |
| SCHEMBL411812 | 0.86 | TGFBR1 (0.62) | TGFBR1THRBMAPK14 | |
| SCHEMBL409613 | 0.84 | TGFBR1 (0.68) | TGFBR1THRBMAPK14 | |
| SCHEMBL413242 | 0.83 | TGFBR1 (0.58) | TGFBR1THRBMAPK14 | |
| SCHEMBL408573 | 0.83 | TGFBR1 (0.75) | TGFBR1THRBMAPK14 | |
| SCHEMBL18123886 | 0.82 | TGFBR1 (0.53) | TGFBR1THRBMAPK14 | |
| SCHEMBL29908639 | 0.82 | TGFBR1 (0.53) | TGFBR1THRBMAPK14 | |
| SCHEMBL413513 | 0.81 | TGFBR1 (0.66) | TGFBR1THRBMAPK14 | |
| SCHEMBL412167 | 0.80 | TGFBR1 (0.60) | TGFBR1THRBMAPK14 | |
| SCHEMBL18115119 | 0.80 | TGFBR1 (0.49) | TGFBR1THRBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | claimed |
| EP-3277673-A1 | TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| WO-2016160881-A1 | TGF-β INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | claimed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | claimed |
| CN-1269820-C | Novel pyrrole derivatives as medicaments | LILLY CO ELI (US) | 2006-08-16 | — | — | CN | claimed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | claimed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | claimed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | claimed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210130361-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| CN-1269820-C | Novel pyrrole derivatives as medicaments | LILLY CO ELI (US) | 2006-08-16 | — | — | CN | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 102/4885MAPK14 2574/4885 |
| US-10822337-B2 | TGF-β inhibitorC | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 193/4885MAPK14 2531/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 102/4885MAPK14 2574/4885 |
| US-20210130361-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 86/4885MAPK14 2664/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885THRB 500/4885MAPK14 546/4885 |
| US-20180086764-A1 | TGF-ß Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 86/4885MAPK14 2664/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885THRB 86/4885MAPK14 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.